Rejuve.AI x Hurdle - New Partnership Announcement

Longevity enthusiasts are a curious bunch. They’re always asking, Should I start taking this? And will that be specifically beneficial for me? The “this” and “that” range from daily multivitamins to at-home hyperbaric chambers — every intervention promising a longer, healthier life.

But without a baseline, it’s impossible to know which intervention is actually moving the needle. Without clear data on what needs attention and whether a chosen strategy is working, the true value of any approach remains ambiguous.

That’s why diagnostics aren’t just useful; they’re non-negotiable.

Diagnostics provide the foundation for every informed decision about health and longevity. They identify areas of concern, track changes over time, and ensure that interventions aren’t just based on hope but measurable progress.

However, getting diagnostic work done isn’t always straightforward. Booking an appointment can take weeks. Certain tests require multiple visits. Some diagnostics remain inaccessible outside of major medical centers.

As we roll out the Rejuve Longevity App — a breakthrough in personal health optimization — we wanted to remove these barriers. Streamlining diagnostics is a critical step toward empowering users with actionable health insights. To do that, we needed a partner with the right expertise, vision, and standards for innovation. We found that partner.

Today, we are proud to announce our new partnership with diagnostics pioneer Hurdle.

Hurdle: Anytime, Anywhere, Anything Diagnostics

Founded in the UK by remarkable scientists from institutions like Cambridge and Oxford, Hurdle pioneered an “anytime, anywhere, anything” diagnostic model. Their approach enables individuals to take charge of their health by offering thousands of clinically validated lab tests that can be ordered and completed at one’s place of convenience — whenever needed.

At the core of Hurdle’s operations is its Diagnostics-as-a-Service (DaaS) platform, which eliminates the bottlenecks of traditional testing. It integrates advanced biomarker research, multi-modal datasets, and AI-driven tools. This enables the development of novel diagnostics, from conception to global scale.

Hurdle’s solutions are built to be modular and scalable, providing entities such as pharmaceutical companies, digital health providers, and research institutions with robust infrastructure for advanced diagnostics.

Through it all, Hurdle upholds the highest standards by employing the latest scientific methods, using validated sample collection devices, and partnering exclusively with laboratories that meet rigorous criteria. This commitment makes advanced diagnostics more accessible without compromising on quality.

A Track Record of Excellence

Hurdle has established a strong presence across both research and industry, working with leading organizations to push the boundaries of diagnostic innovation. Its team includes accomplished scientists whose contributions span dozens of research papers published in journals such as Nature Communications and Aging Cell.

Beyond research, Hurdle collaborates with partners across the healthcare sector to address complex diagnostic challenges and improve patient outcomes. Companies such as Bayer, BioVie, and Lindus Health have worked with Hurdle to develop solutions that enhance the precision and accessibility of diagnostics.

In its impactful collaboration with BioVie, Hurdle helped evaluate the effectiveness of bezisterim, a promising drug candidate for Alzheimer’s disease. One of the key challenges in Alzheimer’s research is the lack of non-invasive biomarkers to track disease progression and treatment response. To address this, Hurdle applied its biomarker discovery engine to BioVie’s phase 3 clinical trial data, tracking biological age in patients receiving bezisterim.

The results showed a measurable reduction in InflammAge, Hurdle’s proprietary epigenetic biomarker for chronic inflammation, with treated individuals displaying an average InflammAge value 4.77 years lower than the placebo group. These findings demonstrate Hurdle’s ability to develop innovative, tailored diagnostic solutions that address critical gaps in research and accelerate medical progress.

Bringing Seamless Diagnostics to the Rejuve Longevity App

The partnership between Rejuve.AI and Hurdle brings a new level of accessibility to longevity-focused diagnostics.

Through this collaboration, users of the Rejuve Longevity App will be able to order Rejuve testing kits for a range of health assessments directly within the app and have the option to pay for them using $RJV. Once completed, the results will be automatically integrated into the app, allowing for seamless tracking and analysis — all made possible by Hurdle’s robust diagnostic infrastructure.

For individuals invested in their long-term health, this removes the friction of conventional testing. No more delays, complicated booking systems, or scattered reports. Instead, users gain direct, data-driven insights into their aging process, helping them make informed decisions about their health.

Beyond personal health, this partnership strengthens the foundation for longevity research. With more individuals accessing convenient diagnostics, the Rejuve Longevity App’s AI models will gain richer, more diverse data. This will refine the app’s ability to provide precise insights on aging while contributing to a broader understanding of longevity trends across different populations.

This is all just the beginning. With the Rejuve Longevity App and luminary partners like Hurdle, a new era of personalized, data-driven longevity is taking shape. Stay tuned for the launch, and get ready to take control of your health like never before.